AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
UBS Upgrades CVS Health to Buy with Price Target of $79
ByAinvest
Tuesday, Aug 19, 2025 3:46 am ET1min read
CVS Health has been upgraded to Buy from Neutral by UBS analyst Kevin Caliendo with a price target of $79, up from $67. The company has shown strong execution and early signs of success in its healthcare benefits segment fixes. UBS sees annual earnings growth of 14% through 2028 for CVS, above the consensus estimate of 12%. The analyst views the valuation as compelling at current share levels.
UBS analyst Kevin Caliendo has upgraded CVS Health (CVS) to a "Buy" rating from "Neutral," with a price target of $79, up from $67. The upgrade reflects strong execution and early signs of success in the company's healthcare benefits segment fixes [1].Caliendo expects CVS to achieve annual earnings growth of 14% through 2028, which is above the consensus estimate of 12%. The analyst believes the current valuation of the stock is compelling at its current share levels. The upgrade comes after CVS reported earnings of $1.81 per share for the last quarter, surpassing the consensus estimate of $1.46, and reported quarterly revenue of $98.92 billion, up 8.4% year-over-year [2].
The upgrade is a significant boost for CVS, which has seen increased interest from institutional investors. Kovitz Investment Group Partners LLC, for instance, grew its holdings in CVS Health by 266.4% during the first quarter, according to its most recent filing with the Securities and Exchange Commission [2].
The analyst's positive outlook on CVS Health is likely to attract more investors, given the company's strong financial performance and promising growth prospects. The upgrade also aligns with the broader market sentiment towards the healthcare sector, which has been experiencing robust growth in recent years.
References:
[1] https://finance.yahoo.com/news/cvs-health-upgraded-occidental-downgraded-133333408.html
[2] https://www.marketbeat.com/instant-alerts/filing-kovitz-investment-group-partners-llc-buys-148703-shares-of-cvs-health-corporation-nysecvs-2025-08-15/
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet